Dianthus Therapeutics | MGTA - Current Liabilities


Dianthus Therapeutics reported $34.39M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Akebia Therapeutics USD 160.86M 13.02M Jun/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Avita Medical AUD 62.68M 77K Dec/2025
Celltrion KRW 292.71B 9.09B Mar/2026
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Deva Holding AS TRY 6.43B 1.18B Sep/2023
Dianthus Therapeutics USD 34.39M 3.89M Jun/2026
Divis Laboratories Ltd INR 20.43B 3.15B Mar/2026
IQVIA Holdings USD 8.82B 486M Jun/2026
Kangmei Pharma CNY 5.38B 433.79M Mar/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 5.56M 2.26M Dec/2025
Moderna USD 2.53B 139M Jun/2026
Neuren Pharmaceuticals AUD 4.34M 3.58M Dec/2025
Organigram Holdings CAD 88.74M 5.31M Mar/2026
Organon & Co USD 2.62B 116M Jun/2026
Ovoca Bio EUR 1.3M 1.11M Dec/2025
Pharma Mar EUR 98.42M 9.2M Jun/2026
Qiagen NV USD 581.45M 102.34M Jun/2026
Revvity USD 1.28B 37.71M Jun/2026
Sartorius EUR 1.44B 668.7M Jun/2026
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Tilray USD 259.32M 8.32M Sep/2025
Viatris USD 6.35B 464.5M Jun/2026
Xeris Pharmaceuticals USD 189.57M 70.97M Jun/2026
Zealand Pharma A/S 404M 260.96M Mar/2026
Zz Pientze Pharmaceu CNY 2.28B 134.52M Mar/2026